

The TITAN-DM study on people with diabetes fully recruited with 600 participants

Coala-Life Group AB (publ), a leading company in cloud-based remote monitoring of heart and lung diseases, announces today that the TITAN-DM study - a clinical observational study aimed at increasing knowledge about the incidence of atrial fibrillation in people with diabetes - is now fully recruited with 600 participants. The study participants are followed with Coala Heart Monitor daily for three months. TITAN-DM is expected to be completed in the spring of 2022 with results for presentation in the autumn of 2022.

"It was natural for us to design a study where the detection of atrial fibrillation during the study period is expected to contribute to direct benefit for the individual and society," says Peter Magnusson, chief physician, with Dr., Region Gävleborg and principal researcher affiliated with Uppsala University and Karolinska Institutet.

People with diabetes have an increased risk of developing atrial fibrillation, a disease that increases the risk of stroke. Atrial fibrillation causes over 10,000 cases of stroke in Sweden every year. It is the most common arrhythmia and there is an increased risk of developing dementia and premature death. In the TITAN-DM study, the Coala Heart Monitor is used to take an ECG daily and detect atrial fibrillation in the study participants during the study. If atrial fibrillation is found, blood-thinning treatment of the NOAK type can be prescribed, which effectively protects against stroke. Recruitment has taken place in collaboration with patient- and senior-citizen organizations.

The pandemic has entailed special challenges and changed conditions for conducting clinical studies. Ability to reach broad geographical and demographic distribution have been limited. In TITAN-DM, recruitment and inclusion has taken place through Bank ID and a completely digital process, enabling broad inclusion throughout Sweden.

"By working with patient associations as a basis for recruitment and a digitized inclusion procedure, we have managed to complete the study in just 12 weeks," comments Michel Tagliati, medical doctor, project manager and CEO of Proaktiv Hälsa.

"It feels important to work to give our members the opportunity to contribute to clinical research that contributes to improving care for people with diabetes," says Veronika Lindberg, head of the Greater Stockholm Diabetes Association.

"Our association and our members want to actively contribute to clinical research. For us, we also saw a direct gain for our members ", says Marie Näslund, head of social policy at the National Association of Pensioners.

About us

Coala Life is a medical device company founded in Sweden focusing on cloud-based cardiac and pulmonary diagnostics. The company has developed and launched the Coala Heart Monitor - a multi-award winning, FDA-cleared and CE-approved product platform enabling long-term remote monitoring, analysis and algorithm-based diagnostics of heart and lungs in real-time. The Coala Heart Monitor is mainly marketed to healthcare providers as an Rx solution for use in patient's everyday life and home environment. The company's solutions are based on over 10 years of R&D, and are protected by more than 30 patents. The head office is based in Uppsala, Sweden and since 2019, the US office is based in Irvine, California. More than 350 care providers and 1,000 doctors are connected to the Coala Care Portal. For more information see www.coalalife.com

For more information, contact:

Dan Pitulia, CEO Coala Life AB
+46 70 972 08 38, dan.pitulia@coalalife.com

Philip Siberg, Co-founder, Chief Strategy Officer and Head of IR
+46 70 790 67 34, philip.siberg@coalalife.com

Attachments

[The TITAN-DM study on people with diabetes fully recruited with 600 participants](#)